NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/21/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization10,897 mln
Float44.46 mln
Earnings Date11/09/2026
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-2.77
Likely reliable
1-Year Forecast
285
Strong upside
Relative Strength
26
/ 100
Underperforming
Debt / Equity
2.70
Very high leverage
ROE
-257
Deeply negative
Business Description
Axsome Therapeutics is a US-based pharmaceutical company focused on developing and commercializing treatments for brain and nervous system conditions. Its current lineup of approved medicines addresses major depression, excessive daytime sleepiness, and migraines. The company also has several drugs in clinical testing aimed at conditions such as Alzheimer's agitation, fibromyalgia, narcolepsy, and attention deficit disorder, among others. Founded in 2012 and headquartered in New York, Axsome works with partners like Duke University to advance its research pipeline.
